A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa
← catalyst calendarNCT06628947 · readout ≤ 377 d
Sponsored by Kiora Pharmaceuticals, Inc. (industry) · KPRX — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
36estimated
Sites
5
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-29 | actual | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-10-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Retinitis Pigmentosa
Interventions
- Other: Placebo (Sterile Saline or Balanced Salt Solution)
- Drug: 100 μg KIO-301
- Drug: 50 μg KIO-301
Primary outcome
what the primary-completion date above is the date OFTo assess the safety and tolerability of multiple doses of KIO-301 administered by IVT injection bilaterally of KIO-301 in patients with late-stage RP.
measured Baseline (Week 1/pre-dose) to Week 25 (12 weeks post 3rd IVT administration of KIO-301)
Permalink · KPRX's whole pipeline · Catalyst calendar · Every registered study · What changed